​The NLRP3 inflammasome triggers an inflammatory response by triggering caspase-1, which releases cytokines of the IL-1 family (Toldo et al. 2022; Broz and Dixit 2016).​ In DCM, the NLRP3 inflammasome is activated and mediates pathogenic pyroptosis (Zeng et al. 2020).​ Therefore, targeting NLRP3 inflammasome activation and related pathways may be a potential therapeutic strategy for the treatment of DCM.​ With the activation of the NLRP3 inflammasome, IL-1β and IL-18 are released, which may trigger and amplify inflammation and lead to cardiac injury in DCM (Harding et al. 2022). This evidence concerns the gene IL18 and familial dilated cardiomyopathy.